AngioSoma and its Subsidiary SomaCeuticals Announce Amended and Restated Execution of Global License for Multiple Sclerosis Patent
AngioSoma Inc. (SOAN) announced an amendment to their Exclusive Global Multiple Sclerosis License Agreement on February 4, 2021, enhancing their collaboration with the licensee to market and license Patent 10,619,592. CEO Alexanderia Blankenship expressed optimism about upcoming trials and potential commercialization if outcomes are favorable. The company, through its subsidiary SomaCeuticals, focuses on innovative wellness products and aims to expand market offerings. This strategic move aligns with the company’s goals for growth in the wellness sector.
- Amended agreement strengthens collaboration for multiple sclerosis patent commercialization.
- Positive outlook for upcoming trials and potential market entry.
- None.
Houston, TX, Feb. 11, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- AngioSoma Inc. (OTC: SOAN) (“AngioSoma” or the “Company”), through its wholly-owned subsidiary, SomaCeuticals, Inc., is pleased to announce that the Exclusive Global Multiple Sclerosis License Agreement dated August 23, 2020 has been amended and restated as of February 4, 2021 to give both parties a stronger and more robust platform to move synergistically forward to market and license Patent 10,619,592 issued to Fabrizio de Silvestri as inventor.
Fabrizio de Silvestri stated, “It is wonderful that Jim Katzaroff and his group are actively interviewing Contract Research Organizations as well as possible funding sources. This looks to be a very exciting and critical year for AngioSoma.”
"I am so delighted that Jim was able to complete this transaction in a favorable manner to both parties. Now Jim will work with alacrity towards trials, and if we receive favorable results, navigate towards commercialization," stated Alexanderia Blankenship, CEO and President of the Company.
About AngioSoma, Inc.
AngioSoma is a wellness company dedicated to bringing innovative, effective and high-quality supplement products and medical devices to the medical, wellness and adult-use markets through our marketing subsidiary, SomaCeuticals™.
Learn more at www.muscles4U.com and htttps://muscles4u.blogstop.com. Stay up to date at Twitter: @tweetmuscles4u, Instagram and Facebook.
Notice Regarding Forward Looking Statements
This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.
CONTACT
AngioSoma, Inc.
James C. Katzaroff
President, SomaCeuticals, Inc.
(832) 781-8521
FAQ
What recent agreement did AngioSoma (SOAN) amend?
How does the amended agreement impact AngioSoma (SOAN)?
What is AngioSoma's focus area as stated in the press release?
What are the expectations for AngioSoma (SOAN) this year?
